Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Capital Expenditures: 2015-2025

Historic Capital Expenditures for Cartesian Therapeutics (RNAC) over the last 10 years, with Sep 2025 value amounting to $1.3 million.

  • Cartesian Therapeutics' Capital Expenditures fell 76.55% to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.7 million, marking a year-over-year decrease of 32.95%. This contributed to the annual value of $9.1 million for FY2024, which is 4314.08% up from last year.
  • Per Cartesian Therapeutics' latest filing, its Capital Expenditures stood at $1.3 million for Q3 2025, which was down 50.21% from $2.6 million recorded in Q2 2025.
  • In the past 5 years, Cartesian Therapeutics' Capital Expenditures registered a high of $5.5 million during Q3 2024, and its lowest value of $12,000 during Q2 2023.
  • Moreover, its 3-year median value for Capital Expenditures was $890,000 (2024), whereas its average is $1.4 million.
  • As far as peak fluctuations go, Cartesian Therapeutics' Capital Expenditures tumbled by 87.88% in 2023, and later soared by 18,875.00% in 2024.
  • Cartesian Therapeutics' Capital Expenditures (Quarterly) stood at $278,000 in 2021, then declined by 24.10% to $211,000 in 2022, then slumped by 69.67% to $64,000 in 2023, then soared by 1,001.56% to $705,000 in 2024, then slumped by 76.55% to $1.3 million in 2025.
  • Its last three reported values are $1.3 million in Q3 2025, $2.6 million for Q2 2025, and $1.1 million during Q1 2025.